Literature DB >> 27025865

Hypoglycaemia in cystic fibrosis in the absence of diabetes: A systematic review.

N Armaghanian1, J C Brand-Miller2, T P Markovic3, K S Steinbeck4.   

Abstract

BACKGROUND: Hypoglycaemia in CF in the absence of diabetes or glucose lowering therapies is a phenomenon that is receiving growing attention in the literature. These episodes are sometimes symptomatic and likely have variable aetiologies. Our first aim was to conduct a systematic review of the literature to determine what is known about hypoglycaemia in CF. Our second aim was to assess evidence based guidelines for management strategies.
METHODS: A comprehensive search of databases and guideline compiler entities was performed. Inclusion criteria were primary research articles and evidence based guidelines that referred to hypoglycaemia in CF in the absence of insulin treatment or other glucose lowering therapies.
RESULTS: A total of 11 studies (four manuscripts and seven abstracts) and five evidence-based guidelines met the inclusion criteria. Prevalence rates of hypoglycaemia unrelated to diabetes varied between studies (7-69%). Hypoglycaemia was diagnosed during oral glucose tolerance testing or continuous glucose monitoring (CGM). Associations between hypoglycaemia and clinical parameters of BMI, lung function, liver disease and pancreatic insufficiency were measured in some studies. There was no unifying definition of hypoglycaemia in the absence of diabetes. Only two evidence based guidelines reported possible management strategies.
CONCLUSION: The systematic review found limited data on this clinical problem and supports the need for high quality methodological studies that are able to describe the experience and the aetiology(ies) of hypoglycaemia in CF.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Continuous glucose monitoring; Cystic fibrosis; Hypoglycaemia; Oral glucose tolerance test

Mesh:

Year:  2016        PMID: 27025865     DOI: 10.1016/j.jcf.2016.02.012

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  6 in total

1.  Hypoglycemia and Islet Dysfunction Following Oral Glucose Tolerance Testing in Pancreatic-Insufficient Cystic Fibrosis.

Authors:  Marissa J Kilberg; Clea Harris; Saba Sheikh; Darko Stefanovski; Marina Cuchel; Christina Kubrak; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels; Andrea Kelly
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

2.  Dysregulated insulin in pancreatic insufficient cystic fibrosis with post-prandial hypoglycemia.

Authors:  Marissa J Kilberg; Saba Sheikh; Darko Stefanovski; Christina Kubrak; Diva D De Leon; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels; Andrea Kelly
Journal:  J Cyst Fibros       Date:  2019-08-08       Impact factor: 5.482

Review 3.  Overview of Atypical Diabetes.

Authors:  Jaclyn Tamaroff; Marissa Kilberg; Sara E Pinney; Shana McCormack
Journal:  Endocrinol Metab Clin North Am       Date:  2020-10-14       Impact factor: 4.741

4.  Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline.

Authors:  Christine L Chan; Timothy Vigers; Laura Pyle; Philip S Zeitler; Scott D Sagel; Kristen J Nadeau
Journal:  J Cyst Fibros       Date:  2018-03-23       Impact factor: 5.482

5.  Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?

Authors:  Mariana Zorron; Fernando Augusto Lima Marson; André Moreno Morcillo; Aline Cristina Gonçalves; Mayra de Souza El Beck; José Dirceu Ribeiro; Antonio Fernando Ribeiro
Journal:  J Bras Pneumol       Date:  2022-04-20       Impact factor: 2.800

6.  Hypoglycemic risk exposures in relation to low serum glucose values in ambulatory patients.

Authors:  Mohammed S Abusamaan; Mark A Marzinke; Aditya Ashok; Karen Carroll; Kyrstin Lane; Rebecca Jeun; Kendall F Moseley; Kathryn A Carson; Nestoras N Mathioudakis
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.